Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Pharmaceutical

Division of Endo International PLC
www.parpharm.com/generics.php

Latest From Par Pharmaceutical

Drug Price Hikes, Shortages Follow FDA Crackdown On Unapproved Drugs

Study finds unintended consequences of FDA initiative requiring manufacturers of unapproved drugs to obtain approval or remove them from the market but FDA says study does not consider broad impact of the initiative.

BioPharmaceutical Regulation

Opana ER Withdrawal Adds Weight To Endo's Ongoing Revenue Decline

With Endo's announcement July 6 that it will conform with FDA's request to remove Opana ER from the market, the specialty firm's prospects seem tied even more tightly to its generics business.

Drug Safety Business Strategies

The End Of Generics Mergers? Too Much Effort, No Reward!

There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.

Generic Drugs M & A

Glenmark Chief Bullish Despite Generic Zetia's Poor US Start

Glenmark Pharmaceuticals reported overall growth in the fourth quarter of 2016-17, but investors bludgeoned the company’s shares on concerns around the slow traction of generic Zetia in the US and a sharp decline in earnings on a sequential basis.

Sales & Earnings Generic Drugs
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register